Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C31H33N3O6S |
| Molecular Weight | 575.6775 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1ccccc1S(=O)(=O)N=C(c2ccc(Cc3cn(C)c4ccc(cc34)N=C(O)OC5CCCC5)c(c2)OC)O
InChI
InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N
InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)
DescriptionCurator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020547s027lbl.pdf
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020547s027lbl.pdf
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma. Patients with asthma were found in one study to be 25-100 times more sensitive to the bronchoconstricting activity of inhaled LTD4 than nonasthmatic subjects. In vitro studies demonstrated that zafirlukast antagonized the contractile activity of three leukotrienes (LTC4, LTD4 and LTE4) in conducting airway smooth muscle from laboratory animals and humans. Zafirlukast prevented intradermal LTD4-induced increases in cutaneous vascular permeability and inhibited inhaled LTD4-induced influx of eosinophils into animal lungs. Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. Zafirlukast is marketed by Astra Zeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Taiwan, Italy, Spain, Canada, Brazil, China and Turkey.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.1 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | ACCOLATE Approved UseACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older. Launch Date8.436096E11 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
352.7 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11888331 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZAFIRLUKAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1090.41 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11888331 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZAFIRLUKAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11888331 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
ZAFIRLUKAST plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
Other AEs: Pharyngitis, Headache... Other AEs: Pharyngitis (24.7%) Sources: Headache (13.8%) Myalgia (3.7%) Sinusitis (3.5%) Flu syndrome (3.3%) Cough increased (3.1%) Rash (3.1%) Rhinitis (3.1%) Accidental injury (3.1%) Nausea (3.1%) Back pain (2.9%) Hypertonia (2.9%) Diarrhea (2.7%) Exacerbation of asthma (2.7%) |
20 mg 2 times / day multiple, oral Highest studied dose Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 37 n = 67 Health Status: unhealthy Condition: asthma, moderate Age Group: 37 Sex: M+F Population Size: 67 Sources: |
Other AEs: Headache, Gastritis... Other AEs: Headache (7%) Sources: Gastritis (1%) Pharyngitis (20%) Rhinitis (7%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Headache | 13.8% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Diarrhea | 2.7% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Exacerbation of asthma | 2.7% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Back pain | 2.9% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Hypertonia | 2.9% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Pharyngitis | 24.7% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Accidental injury | 3.1% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Cough increased | 3.1% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Nausea | 3.1% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Rash | 3.1% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Rhinitis | 3.1% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Flu syndrome | 3.3% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Sinusitis | 3.5% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Myalgia | 3.7% | 20 mg 2 times / day multiple, oral Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 12-76 n = 514 Health Status: unhealthy Condition: asthma, mild-to-moderate Age Group: 12-76 Sex: M+F Population Size: 514 Sources: |
| Gastritis | 1% | 20 mg 2 times / day multiple, oral Highest studied dose Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 37 n = 67 Health Status: unhealthy Condition: asthma, moderate Age Group: 37 Sex: M+F Population Size: 67 Sources: |
| Pharyngitis | 20% | 20 mg 2 times / day multiple, oral Highest studied dose Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 37 n = 67 Health Status: unhealthy Condition: asthma, moderate Age Group: 37 Sex: M+F Population Size: 67 Sources: |
| Headache | 7% | 20 mg 2 times / day multiple, oral Highest studied dose Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 37 n = 67 Health Status: unhealthy Condition: asthma, moderate Age Group: 37 Sex: M+F Population Size: 67 Sources: |
| Rhinitis | 7% | 20 mg 2 times / day multiple, oral Highest studied dose Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: |
unhealthy, 37 n = 67 Health Status: unhealthy Condition: asthma, moderate Age Group: 37 Sex: M+F Population Size: 67 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. | 2001 |
|
| Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma. | 2001 |
|
| Pharmacology of airway afferent nerve activity. | 2001 |
|
| Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. | 2001 |
|
| Comparative efficacy of inhaled corticosteroids and antileukotriene drugs in asthma. | 2001 |
|
| A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. | 2001 Aug 15 |
|
| Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. | 2001 Jul |
|
| Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. | 2001 Jul 5 |
|
| Efficacy of antileukotriene agents in asthma management. | 2001 Jun |
|
| Discovery of leukotrienes and development of antileukotriene agents. | 2001 Jun |
|
| The role of antileukotrienes in the treatment of asthma. | 2001 Jun |
|
| Safety of antileukotriene agents in asthma management. | 2001 Jun |
|
| Role of cysteinyl leukotrienes in nociceptive and inflammatory conditions in experimental animals. | 2001 Jun 29 |
|
| Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene1-receptor blockade in human bronchus. | 2001 May 11 |
|
| Molecular cloning and functional characterization of murine cysteinyl-leukotriene 1 (CysLT(1)) receptors. | 2001 Nov 1 |
|
| Severe liver injury associated with zafirlukast. | 2001 Nov 20 |
|
| The effect of low-dose inhaled fluticasone propionate on exhaled nitric oxide in asthmatic patients and comparison with oral zafirlukast. | 2001 Oct |
|
| Asthma treatment with inhaled corticosteroids versus antileukotrienes: what exhaled nitric oxide studies do and do not tell us. | 2001 Oct |
|
| Acute hepatocellular injury associated with zafirlukast. | 2001 Oct |
|
| Zafirlukast-related hepatitis: report of a further case. | 2001 Oct |
|
| [Leukotriene modifiers]. | 2001 Oct |
|
| Leukotriene receptor antagonists in the treatment of allergic rhinitis. | 2001 Oct |
|
| Severe liver injury. | 2001 Oct 2 |
|
| Chronic asthma. | 2001 Oct 27 |
|
| Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. | 2001 Sep |
|
| Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal. | 2001 Sep |
|
| Leukotriene receptor antagonists in the treatment of asthma: an update. | 2002 |
|
| Where do leukotriene modifiers fit in asthma management? | 2002 Apr |
|
| [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]. | 2002 Apr |
|
| Pharmacogenetics of asthma. | 2002 Apr 1 |
|
| Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. | 2002 Apr 15 |
|
| [Reflections on antileukotrienes]. | 2002 Apr 15 |
|
| Vasculitis induced by zafirlukast therapy. | 2002 Aug |
|
| Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. | 2002 Aug 1 |
|
| Participation of chemical mediators other than histamine in nasal allergy signs: a study using mice lacking histamine H(1) receptors. | 2002 Aug 9 |
|
| [Churg-Strauss syndrome after treatment with Singulair (montelukast)]. | 2002 Feb 20 |
|
| Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. | 2002 Jul |
|
| Efficacy and safety of low-dose fluticasone propionate compared with zafirlukast in patients with persistent asthma. | 2002 Jul |
|
| Churg-Strauss syndrome in a case of asthma. | 2002 Jul |
|
| 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. | 2002 Jun |
|
| Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. | 2002 Jun |
|
| Pulmonary function changes and immunomodulation of cytokine expression by zafirlukast after sensitization and allergen challenge in brown Norway rats. | 2002 Jun |
|
| Novel phthalimide derivatives, designed as leukotriene D(4) receptor antagonists. | 2002 Jun 3 |
|
| [Zafirlukast in treatment of nasal polyps in patients with aspirin intolerant bronchial asthma--preliminary report]. | 2002 Mar |
|
| Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. | 2002 Mar |
|
| Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study. | 2002 Mar |
|
| Inhaled fluticasone and zafirlukast in persistent asthma. | 2002 Mar |
|
| [Aspirin induced asthma, urinary leukotriene E4 and zafirlukast]. | 2002 Mar-Apr |
|
| Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. | 2002 May |
|
| [New horizons in the treatment of atopic dermatitis]. | 2002 May-Jun |
Sample Use Guides
Should be taken at least 1 hour before or 2 hours after meals. Adults and Children 12 years of age and older
The recommended dose of ACCOLATE in adults and children 12 years and older is 20 mg twice daily. Pediatric Patients 5 through 11 years of age
The recommended dose of ACCOLATE in children 5 through 11 years of age is 10 mg twice daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NDF-RT |
N0000175777
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
||
|
NDF-RT |
N0000000083
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
||
|
NCI_THESAURUS |
C29712
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
||
|
LIVERTOX |
1043
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
||
|
WHO-ATC |
R03DC01
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
||
|
WHO-VATC |
QR03DC01
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
107753-78-6
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
M11576
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | Merck Index | ||
|
7244
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
XZ629S5L50
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
SUB00128MIG
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
CHEMBL603
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
C47785
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
5717
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
3322
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
DB00549
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
107753-78-6
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
Zafirlukast
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
ZAFIRLUKAST
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
2855
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
C062735
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | |||
|
114970
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | RxNorm | ||
|
N0000185504
Created by
admin on Fri Jun 25 23:37:48 UTC 2021 , Edited by admin on Fri Jun 25 23:37:48 UTC 2021
|
PRIMARY | Cytochrome P450 2C9 Inhibitors [MoA] |
ACTIVE MOIETY
